Liquid Biopsy Market Size, Share, Growth Insights and Report 2024-2031 | Exosome Sciences Inc, Grail Inc, Guardant Health

Liquid Biopsy Market Research Report By DataM Intelligence: A comprehensive analysis of current and emerging trends provides clarity on the dynamics of the Liquid Biopsy market. The report employs Porter's Five Forces model to assess key factors such as the influence of suppliers and customers, risks posed by different entities, competitive intensity, and the potential of emerging entrepreneurs, offering valuable insights. Additionally, the report presents research data from various companies, including their benefits, gross margins, and strategic decisions in the global market, all conveyed through tables, charts, and infographics.

Download Free Sample PDF: https://datamintelligence.com/download-sample/liquid-biospy-market

What is the projected growth rate (CAGR) of the Global Liquid Biopsy market from 2024 to 2031, and what is the market value expected to change by 2031?

Global Liquid Biopsy Market reached USD 4.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 12.3 billion by 2030. The Global Liquid Biopsy Market is expected to exhibit a CAGR of 15.4% during the forecast period 2024-2031.

What is Liquid Biopsy Market?

A liquid biopsy is a minimally invasive test that analyzes a sample of bodily fluid, such as blood, to detect cancer cells, DNA fragments, or other biomarkers associated with tumors. Unlike traditional tissue biopsies, which require a surgical procedure, liquid biopsies offer a quick and accessible way to monitor cancer presence, progression, and response to treatment over time. This technique is particularly valuable in detecting early-stage cancers, tracking metastasis, and identifying genetic mutations that may guide personalized treatments. Liquid biopsies hold promise for improving cancer diagnosis and management with reduced discomfort and lower risk to patients.

Growth Driver

Recent Advances in Liquid Biopsy Technologies Drive Market Growth

Significant advancements in liquid biopsy technologies have enhanced the detection and analysis of cancer biomarkers, propelling growth in the liquid biopsy market. These innovations have improved the sensitivity, specificity, and throughput of liquid biopsy assays, making them more reliable for clinical applications.

For example, Next-Generation Sequencing (NGS) has transformed liquid biopsy by enabling detailed analysis of genetic alterations in circulating tumor DNA (ctDNA). According to a 2022 article from the Royal Society of Chemistry, NGS-based assays can detect multiple genetic mutations, copy number variations, and structural changes in a single test. This technology has made liquid biopsy panels increasingly accurate, sensitive, and cost-effective, allowing for the identification of targetable mutations and personalized treatment options.

In addition, protein-based liquid biopsy approaches are gaining traction, as they can detect cancer-related proteins or protein signatures in blood and other bodily fluids. Techniques such as immunoassays, mass spectrometry, and microfluidic platforms enable the analysis of protein biomarkers, providing crucial insights into early cancer detection, treatment efficacy, and residual disease presence.

These advancements underscore the role of liquid biopsy in personalized medicine, supporting early cancer detection and precise treatment selection, and are expected to continue driving market growth in the coming years.

Key Players:

Profiles of some of the major players in the global Liquid Biopsy market, which include: Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV.

Industry Development:

On April 18, 2023, Stilla Technologies announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR platform, the naica system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications.

On November 30, 2022, Thermo Fisher Scientific released a slew of dPCR Liquid Biopsy assays for their Applied Biosystems Absolute Q dPCR system and a custom design tool to help with cancer research.

The purpose of the report is to offer a comprehensive analysis of the market, along with insightful conclusions, statistical data, historical information, market data that has been confirmed by the industry, and predictions based on a sound methodology. By identifying and examining market segments and forecasting global market size, the study also contributes to understanding the dynamics and structure of the global Liquid Biopsy market.

Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=liquid-biospy-market

Market Segments:

By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles and Others)

By Product & Services (Kits & Reagents, Instruments, Services)

By Applications (Cancer Applications (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Other Cancers), Non-Cancer Applications)

By End User (Hospitals and Physician Laboratories, Research Centers and Others)

The report covers the segmentation of the market into different segments based on various classifications such as applications, end users, product types, and others. The segmentation is divided into two sections, one for development and the other for different roles, needs, and behaviours.

Regional Break out:

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/liquid-biospy-market

Key Features

➧ Gain deep insights into market dynamics, trends, and opportunities to stay ahead in a competitive landscape.

➧ Track competitor's movements in real time, allowing you to swiftly adapt strategies and remain competitive.

➧ Compare your performance with industry leaders to identify gaps, strengths, and areas for improvement.

➧ Stay updated with emerging market trends, technological advancements, and customer behaviour to refine your strategy.

➧ Receive actionable insights and recommendations to drive your business toward growth and long-term success.

➧ Tailor competitive intelligence to your unique business needs, ensuring relevant and focused analysis.

➧ Evaluate supply chain efficiency and logistics strategies to optimize operations and minimize disruptions.

➧ Understand key players, stakeholders, and partnerships to navigate the competitive landscape more effectively.

➧ Identify and target specific market segments with detailed intelligence on customer preferences and behaviours.

➧ Stay informed on regulatory changes and legal requirements impacting your industry to ensure compliance and mitigate risks.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.